Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
J Med Internet Res. 2021 Dec 20;23(12):e31321. doi: 10.2196/31321.
Accurate medication reconciliation reduces the risk of drug incompatibilities and adverse events that can occur during transitions in care. Community pharmacies (CPs) are a crucial part of the health care system and could be involved in collecting essential information on conventional and supplementary drugs used at home.
The aim of this paper was to establish an alliance between our cancer institute, Istituto Romagnolo per lo Studio dei Tumori (IRST), and CPs, the latter entrusted with the completion of a pharmacological recognition survey. We also aimed to integrate the national information technology (IT) platform of CPs with the electronic medical records of IRST.
Cancer patients undergoing antiblastic treatments were invited to select a CP taking part in the study and to complete the pharmacological recognition step. The information collected by the pharmacist was sent to the electronic medical records of IRST through the new IT platform, after which the oncologist performed the reconciliation process.
A total of 66 CPs completed surveys for 134 patients. An average of 5.9 drugs per patient was used at home, with 12 or more used in the most advanced age groups. Moreover, 60% (80/134) of the patients used nonconventional products or critical foods. Some potential interactions between nonconventional medications and cancer treatments were reported.
In the PROF-1 (Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna) study, an alliance was created between our cancer center and CPs to improve medication reconciliation, and a new integrated IT platform was validated.
ClinicalTrials.gov NCT04796142; https://clinicaltrials.gov/ct2/show/NCT04796142.
准确的用药核对可以降低药物不相容和转院期间不良事件的风险。社区药房（CPs）是医疗保健系统的重要组成部分，可参与收集在家中使用的常规和补充药物的基本信息。
本文旨在建立我们的癌症研究所（Istituto Romagnolo per lo Studio dei Tumori [IRST]）与 CPs 之间的联盟，后者负责完成药物识别调查。我们还旨在将 CPs 的国家信息技术（IT）平台与 IRST 的电子病历集成。
接受抗肿瘤治疗的癌症患者被邀请选择参与研究的 CPs 并完成药物识别步骤。药剂师收集的信息通过新的 IT 平台发送到 IRST 的电子病历，然后肿瘤学家进行核对过程。
共有 66 家 CPs 为 134 名患者完成了调查。平均每位患者在家中使用 5.9 种药物，在年龄较大的患者中使用 12 种或更多药物。此外，60%（134 名患者中的 80 名）使用非传统产品或关键食品。报告了一些非传统药物与癌症治疗之间的潜在相互作用。
在 PROF-1（Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna）研究中，我们的癌症中心与 CPs 之间建立了联盟，以改善用药核对，并验证了一个新的集成 IT 平台。
ClinicalTrials.gov NCT04796142；https://clinicaltrials.gov/ct2/show/NCT04796142。
